TY - JOUR
T1 - Prospective, multicenter study of antimicrobial-coated, noncrosslinked, acellular porcine dermal matrix (XenMatrix™ AB Surgical Graft) for hernia repair in all centers for disease control and prevention wound classes
T2 - 24-month follow-up cohort
AU - Hahi, Obeid N.
AU - Velmahos, George
AU - Janis, Jeffrey E.
AU - Kovach, Stephen J.
AU - McLean, Susan F.
AU - Askari, Reza
AU - Sommer, Courtney A.
AU - Agarwal, Suresh
AU - Srinivasan, Jahnavi
AU - Wong, Alex K.
AU - Pakula, Andrea
AU - Miranda, Edward P.
AU - Breen, Kerry
AU - Shapiro, Mark
AU - Deeken, Corey R.
AU - Stringer, R. Cody
AU - McGraw, J. Reed
AU - Bascone, Corey
AU - Martindale, Robert G.
N1 - Publisher Copyright:
© 2023 The Author(s). Published by Wolters Kluwer Health, Inc. This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
PY - 2023/5/1
Y1 - 2023/5/1
N2 - Background: Prospective, multicenter, single-arm study of antimicrobial-coated, noncrosslinked, acellular porcine dermal matrix (AC-PDM) in a cohort involving all centers for disease control and prevention wound classes in ventral/incisional midline hernia repair (VIHR). Materials and methods: Seventy-five patients (mean age 58.6 ± 12.7 years; BMI 31.3 ± 4.9 kg/m2) underwent ventral/incisional midline hernia repair with AC-PDM. Surgical site occurrence (SSO) was assessed in the first 45 days post-implantation. Length of stay, return to work, hernia recurrence, reoperation, quality of life, and SSO were assessed at 1, 3, 6, 12, 18, and 24 months. Results: 14.7% of patients experienced SSO requiring intervention within 45 days post-implantation, and 20.0% thereafter (> 45 d post-implantation). Recurrence (5.8%), definitely device-related adverse events (4.0%), and reoperation (10.7%) were low at 24 months; all quality-of-life indicators were significantly improved compared to baseline. Conclusion: AC-PDM exhibited favourable results, including infrequent hernia recurrence and definitely device-related adverse events, with reoperation and SSO comparable to other studies, and significantly improved quality of life.
AB - Background: Prospective, multicenter, single-arm study of antimicrobial-coated, noncrosslinked, acellular porcine dermal matrix (AC-PDM) in a cohort involving all centers for disease control and prevention wound classes in ventral/incisional midline hernia repair (VIHR). Materials and methods: Seventy-five patients (mean age 58.6 ± 12.7 years; BMI 31.3 ± 4.9 kg/m2) underwent ventral/incisional midline hernia repair with AC-PDM. Surgical site occurrence (SSO) was assessed in the first 45 days post-implantation. Length of stay, return to work, hernia recurrence, reoperation, quality of life, and SSO were assessed at 1, 3, 6, 12, 18, and 24 months. Results: 14.7% of patients experienced SSO requiring intervention within 45 days post-implantation, and 20.0% thereafter (> 45 d post-implantation). Recurrence (5.8%), definitely device-related adverse events (4.0%), and reoperation (10.7%) were low at 24 months; all quality-of-life indicators were significantly improved compared to baseline. Conclusion: AC-PDM exhibited favourable results, including infrequent hernia recurrence and definitely device-related adverse events, with reoperation and SSO comparable to other studies, and significantly improved quality of life.
KW - XenMatrix AB surgical graft
KW - hernia repair
KW - minocycline
KW - porcine dermal matrix
KW - rifampin
KW - surgical site occurrence
UR - https://www.scopus.com/pages/publications/85161577305
U2 - 10.1097/MS9.0000000000000695
DO - 10.1097/MS9.0000000000000695
M3 - Article
AN - SCOPUS:85161577305
SN - 2049-0801
VL - 85
SP - 1571
EP - 1577
JO - Annals of Medicine and Surgery
JF - Annals of Medicine and Surgery
IS - 5
ER -